Creative Biolabs, a global CRO specializing in antibody-drug conjugates (ADCs), is highlighting its integrated bispecific and biparatopic ADC development capabilities.



SHIRLEY, NY, September 17, 2026 /24-7PressRelease/ -- This service suite is designed to empower global biopharmaceutical companies to rigorously evaluate and accelerate the design of targeted bispecific ADCs.

Introduction and Platform Focus
While traditional monoclonal ADCs have advanced oncology, developers frequently encounter hurdles such as suboptimal internalization rates and acquired drug resistance. To address these challenges, Creative Biolabs focuses on multi-specific targeting mechanisms, providing an end-to-end solution from early discovery to preclinical evaluation.

A biparatopic ADC is a type of bispecific ADC designed to engage two non-overlapping epitopes on the same target antigen.

Scientific Mechanism and Preclinical Applications
Depending on epitope selection, molecular format, and target biology, biparatopic engagement may promote receptor clustering and enhance internalization and lysosomal trafficking. These properties can be evaluated experimentally to guide antibody format, linker, and payload selection, with the goal of improving intracellular payload delivery while allowing safety-related properties to be evaluated through appropriate in vitro and in vivo studies.

One of the key preclinical development applications of this strategy is in solid tumors, particularly breast and gastric cancers. Heterogeneous target expression, limited receptor internalization, and resistance to prior HER2-directed therapies can complicate the development of HER2-targeted ADCs. Biparatopic formats offer one investigational strategy for evaluating whether dual-epitope engagement can improve receptor trafficking or activity in selected models, supporting the preclinical evaluation of new ADC candidates for HER2-expressing solid tumor programs.

"Biparatopic ADC development requires more than combining two binding arms," said a senior scientist at Creative Biolabs. "Epitope geometry, molecular format, internalization behavior, conjugation strategy, and payload properties must be evaluated together to identify a developable candidate."

Comprehensive ADC Development Workflow
To support data-driven pipeline decisions and address specific development bottlenecks, Creative Biolabs offers a comprehensive, integrated workflow. This service chain helps clients answer critical development questions through:

Identifying optimal epitope combinations: Precise epitope mapping and pair screening to find the most effective dual-binding strategies.
Selecting the right molecular format: Rigorous screening and comparison of bispecific formats, stability, aggregation, and expression levels.
Verifying enhanced internalization: Quantitative internalization and lysosomal colocalization assays to confirm intracellular delivery.
Matching payload to target biology: Tailored linker-payload selection, conjugation, and bystander-effect evaluation.
Assessing downstream developability: Thorough Drug-to-Antibody Ratio (DAR) characterization, purity and stability testing, alongside in vivo pharmacokinetic (PK), preliminary safety, and efficacy profiling.

Equipped with state-of-the-art laboratory facilities, Creative Biolabs covers the entire pipeline of ADC development, offering customized solutions to accelerate the translation of innovative concepts into rigorously tested preclinical candidates.

For more information, please visit https://www.creative-biolabs.com/adc/.

About Creative Biolabs
Creative Biolabs is a leading service provider that covers the entire pipeline of antibody-drug conjugate (ADC) development. With years of experience and specialized platforms, the company offers customized solutions for antibody discovery, linker-payload design, bioconjugation, and comprehensive preclinical testing, accelerating the translation of innovative concepts into life-saving therapeutics.

Read the original story here: https://www.24-7pressrelease.com/press-release/538707/creative-biolabs-highlights-integrated-bispecific-adc-development-services-for-biparatopic-programs

Press Release Service and Press Release Distribution by 24-7 Press Release Newswire